Filter By:

Reset
Renal Research

Research activity in the Renal Research program at PHRI includes treatment of patients who require dialysis, severe glomerular disease, and perioperative acute kidney injury, and various forms of chronic kidney diseases.

Team Members in Renal

Michael Walsh

Scientist

Michael Walsh
Scientist

Michael Walsh is a Principal Investigator in the Renal research program at PHRI, and an Assistant Professor, Department of Medicine (nephrology), McMaster University. His research activities are in the areas of the treatment of patients who require dialysis, severe glomerular disease, and perioperative acute kidney injury. He has published more than 70 papers and two book chapters.

He holds a Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator award through CIHR and the Kidney Foundation of Canada.  He’s received multiple Top Abstract awards from the Canadian Society of Nephrology, the Chalmers Prize from the Society for Clinical Trials, and the Detweiller Traveling Scholar Award from the College of Physicians and Surgeons of Canada.

Matthew Lanktree

Investigator

Matthew Lanktree
Investigator

Matthew Lanktree is a clinical scientist in adult nephrology genetics who cares for patients with chronic and end-stage kidney disease at St. Joseph’s Healthcare Hamilton and Hamilton Health Sciences. He is an Assistant Professor, Department of Medicine (division of nephrology) and Department of Health Research, Methods, Evidence and Impact, at McMaster University. His research areas of interest are: nephrology genetics; cardiovascular disease in patients with chronic kidney disease; dialysis; and polycystic kidney disease.

He obtained a combined MD and PhD at Western University with research in human genetics before residency in internal medicine and nephrology at McMaster University. He then completed a post-doctoral research fellowship in heritable kidney disease at the University of Toronto before returning to McMaster as faculty in 2019. He has published more than 60 articles in high-impact journals in genetics and medicine, and has set his goal to translate genetic studies into improved care of patients with kidney disease.

Amber Molnar

Associate Investigator

Amber Molnar
Associate Investigator

Amber Molnar is a nephrologist at St. Joseph’s Healthcare in Hamilton, and Assistant Professor, Department of Medicine, Division of Nephrology, McMaster University. Her research program focuses on improving the pre-dialysis care of patients with advanced chronic kidney disease (CKD) and reducing cardiovascular complications in patients with CKD.

She holds a Kidney Research Scientist Core Education and National Training (KRESCENT) program’s New Investigator Award through CIHR and the Kidney Foundation of Canada. Amber earned her M.D. at the University of Saskatchewan followed by internal medicine training at Western University, and completed her nephrology and MSc (Epidemiology) training at the University of Ottawa.

Tara McCready

Program Director

Tara McCready
Program Director

Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.

She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.

Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.

ongoing

ACHIEVE

Renal

Globally more than two million people receive dialysis for end-stage renal disease (ESRD) and 650,000...

ongoing

DISCO-RLS

Renal

Restless legs syndrome (RLS) affects 30% of dialysis patients and is associated with a decreased...

ongoing

RECORD

Renal

The Registry of persons with kidney disease Considering participation in Research Database (RECORD) stems from...

ongoing

Risk Factors for Suboptimal Dialysis Initiation

Renal

At the end of 2014, 20,690 Canadians were receiving chronic dialysis. Unfortunately, many of these...

completed

PHASE

Renal

Mineralocorticoid receptor antagonism reduces morbidity and mortality in patients with heart failure, but the safety...

completed

TARGET

Renal

The TARGET trial investigated intensive versus liberalized phosphate control in hemodialysis recipients. The objective of...

completed

416858-CS4

Renal

The objective of the 416858-CS4 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics...

Back To Top